National Securities Initiates Coverage on Dyax (DYAX) with a Buy
More News related to DYAX
- KALBITOR(R) (ecallantide) Now Commercially Available
- Dyax Corp. to Present at the BIO CEO & Investor Conference
- Dyax Launches HAE Hope, A New Online Resource for Patients with Hereditary Angioedema
- Wedbush Reiterates an 'Outperform' on Dyax Corp. (DYAX); Lowers Fair Value Estimate
- Morning Movers 12/03: ICOC, KTCC, FFHL, GNBT, ABK, ISR Higher; PEIX, GRH, OPXA, TRGT, ALOY Lower
More News related to New Coverage
- Sidoti & Co Initiates Coverage on Solutia (SOA) with a Buy
- RBC Capital Initiates Coverage on Questar (STR) with a Sector Perform
- Needham & Company Starts Time Warner (TWX) at Hold
- Standpoint Research Starts City Holding Co. (CHCO) at Buy
- Benchmark Securities Initiates Coverage on Vitacost.com (VITC) with a Buy.
National Securities initiates coverage on Dyax (Nasdaq: DYAX) with a Buy. Price target $5.
To see more analyst ratings on DYAX Click Here.
Dyax Corp., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of biotherapeutics for oncology and inflammatory indications.
Related Categories
New CoverageStocks Mentioned
+0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
